FilingSEC EDGAR8-K
Keros Therapeutics Receives $20 Million Milestone and Authorizes Share Repurchase
· SEC accepted
StageApproved
Filing content
The company received a $20 million development milestone from Takeda and authorized a share repurchase program of up to $5 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…